Intravenous immunoglobulin reduces beta amyloid and abnormal tau formation caused by herpes simplex virus type 1

Journal of Neuroimmunology

Volumn 257, Issue 1-2, 2013, Pages 7-12

  Wozniak, Matthew A ^a   Itzhaki, Ruth F ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Amyloid; Abnormally phosphorylated tau; Acyclovir; Alzheimer's disease; Herpes simplex virus type 1; Intravenous immunoglobulin

Indexed keywords

ACICLOVIR; AMYLOID BETA PROTEIN; HERPES SIMPLEX VIRUS 1 PROTEIN; IMMUNOGLOBULIN G; TAU PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; HERPES SIMPLEX VIRUS 1; IMMUNOCYTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; VERO CELL; VIRUS ENTRY; VIRUS REPLICATION;

AMYLOID BETA-PEPTIDES; ANIMALS; CERCOPITHECUS AETHIOPS; HERPESVIRUS 1, HUMAN; IMMUNOGLOBULINS, INTRAVENOUS; TAU PROTEINS; VERO CELLS; VIRAL STRUCTURAL PROTEINS;

EID: 84875806478     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.01.005     Document Type: Article

References (18)

1. Alvarez G., Aldudo J., Alonso M., Santana S., Valdivieso F. Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J. Neurosci. Res. 2012, 90:1020-1029.
2. Bayry J., Lacroix-Desmazes S., Kazatchkine M.D., Kaveri S.V. Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?. Trends Pharmacol. Sci. 2004, 25:306-310.
3. Devi G., Schultz S., Khosrowshahi L., Agnew A., Olali E. A retrospective chart review of the tolerability and efficacy of intravenous immunoglobulin in the treatment of Alzheimer's disease. J. Am. Geriatr. Soc. 2008, 56:772-774.
4. Dobson C.B., Sales S.D., Hoggard P., Wozniak M.A., Crutcher K.A. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J. Infect. Dis. 2006, 193:442-450.
5. Erlich K.S., Mills J. Passive immunotherapy for encephalitis caused by herpes simplex virus. Rev. Infect. Dis. 1986, 8(Suppl. 4):S439-S445.
6. Fillit H., Hess G., Hill J., Bonnet P., Toso C. IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders. Neurology 2009, 73:180-185.
7. Itzhaki R.F., Lin W.R., Shang D., Wilcock G.K., Faragher B., Jamieson G.A. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet 1997, 349:241-244.
8. Jamieson G.A., Maitland N.J., Wilcock G.K., Craske J., Itzhaki R.F. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. J. Med. Virol. 1991, 33:224-227.
9. Jamieson G.A., Maitland N.J., Wilcock G.K., Yates C.M., Itzhaki R.F. Herpes simplex virus type 1 DNA is present in specific regions of brain from aged people with and without senile dementia of the Alzheimer type. J. Pathol. 1992, 167:365-368.
10. Kohl S., Loo L.S. In vitro and in vivo antibody-dependent cellular cytotoxicity of intravenous immunoglobulin G preparations against herpes simplex virus. Rev. Infect. Dis. 1986, 8(Suppl. 4):S446-S448.
11. Lin W.R., Graham J., MacGowan S.M., Wilcock G.K., Itzhaki R.F. Alzheimer's disease, herpes virus in brain, apolipoprotein E4 and herpes labialis. Alzheimers Rep. 1998, 1:173-178.
12. Masci S., De Simone C., Famularo G., Gravante M., Ciancarelli M., Andreassi M., Amerio P., Santini G. Intravenous immunoglobulins suppress the recurrences of genital herpes simplex virus: a clinical and immunological study. Immunopharmacol. Immunotoxicol. 1995, 17:33-47.
13. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging 2009, 30:1728-1736.
14. Wozniak M.A., Shipley S.J., Combrinck M., Wilcock G.K., Itzhaki R.F. Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients. J. Med. Virol. 2005, 75:300-306.
15. Wozniak M.A., Itzhaki R.F., Shipley S.J., Dobson C.B. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci. Lett. 2007, 429:95-100.
16. Wozniak M.A., Frost A.L., Itzhaki R.F. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J. Alzheimers Dis. 2009, 16:341-350.
17. Wozniak M.A., Mee A.P., Itzhaki R.F. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J. Pathol. 2009, 217:131-138.
18. Wozniak M.A., Frost A.L., Preston C.M., Itzhaki R.F. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS One 2011, 6:e25152.